These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 16206347

  • 1. Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway.
    Madland TM, Apalset EM, Johannessen AE, Rossebö B, Brun JG.
    J Rheumatol; 2005 Oct; 32(10):1918-22. PubMed ID: 16206347
    [Abstract] [Full Text] [Related]

  • 2. Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway.
    Nossent JC, Gran JT.
    Scand J Rheumatol; 2009 Oct; 38(4):251-5. PubMed ID: 19247847
    [Abstract] [Full Text] [Related]

  • 3. Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course.
    Love TJ, Gudbjornsson B, Gudjonsson JE, Valdimarsson H.
    J Rheumatol; 2007 Oct; 34(10):2082-8. PubMed ID: 17696270
    [Abstract] [Full Text] [Related]

  • 4. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.
    Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE.
    J Rheumatol; 2000 May; 27(5):1247-50. PubMed ID: 10813295
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A.
    Gül U, Gönül M, Kiliç A, Erdem R, Cakmak SK, Gündüz H.
    Clin Ther; 2006 Feb; 28(2):251-4. PubMed ID: 16678646
    [Abstract] [Full Text] [Related]

  • 7. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate?
    Lacaille D, Stein HB, Raboud J, Klinkhoff AV.
    J Rheumatol; 2000 Aug; 27(8):1922-7. PubMed ID: 10955334
    [Abstract] [Full Text] [Related]

  • 8. Resistant cases of psoriatic arthritis: how to manage them.
    Atzeni F, Sarzi-Puttini P, Vena GA.
    J Rheumatol Suppl; 2009 Aug; 83():73-5. PubMed ID: 19661549
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
    Kristensen LE, Gülfe A, Saxne T, Geborek P.
    Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
    [Abstract] [Full Text] [Related]

  • 10. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study.
    Niccoli L, Nannini C, Cassarà E, Kaloudi O, Susini M, Lenzetti I, Cantini F.
    Int J Rheum Dis; 2012 Aug; 15(4):414-8. PubMed ID: 22898222
    [Abstract] [Full Text] [Related]

  • 11. The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis.
    Makredes M, Robinson D, Bala M, Kimball AB.
    J Am Acad Dermatol; 2009 Sep; 61(3):405-10. PubMed ID: 19700012
    [Abstract] [Full Text] [Related]

  • 12. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis.
    Reich K, Krüger K, Mössner R, Augustin M.
    Br J Dermatol; 2009 May; 160(5):1040-7. PubMed ID: 19210498
    [Abstract] [Full Text] [Related]

  • 13. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.
    Cantini F, Niccoli L, Nannini C, Cassarà E, Pasquetti P, Olivieri I, Salvarani C.
    Rheumatology (Oxford); 2008 Jun; 47(6):872-6. PubMed ID: 18400836
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
    Helliwell PS, Taylor WJ, CASPAR Study Group.
    J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
    [Abstract] [Full Text] [Related]

  • 16. [Prevalence of psoriatic arthritis in a population of patients with psoriasis].
    Jajić Z, el Assadi G.
    Acta Med Croatica; 2003 Mar; 57(4):323-6. PubMed ID: 14639870
    [Abstract] [Full Text] [Related]

  • 17. Epidemiology of psoriatic arthritis in northwest Greece, 1982-2001.
    Alamanos Y, Papadopoulos NG, Voulgari PV, Siozos C, Psychos DN, Tympanidou M, Drosos AA.
    J Rheumatol; 2003 Dec; 30(12):2641-4. PubMed ID: 14719208
    [Abstract] [Full Text] [Related]

  • 18. Prevalence of monoclonal gammopathy among patients with psoriatic arthritis.
    Eder L, Thavaneswaran A, Pereira D, Sussman G, Gladman DD.
    J Rheumatol; 2012 Mar; 39(3):564-7. PubMed ID: 22247355
    [Abstract] [Full Text] [Related]

  • 19. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis.
    Yang Q, Qu L, Tian H, Hu Y, Peng J, Yu X, Yu C, Pei Z, Wang G, Shi B, Zhang F, Zhang Y, Zhang F.
    J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1409-14. PubMed ID: 21349114
    [Abstract] [Full Text] [Related]

  • 20. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, Reynolds A, Emery P.
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.